CytomX previously reported preliminary progression-free survival of 6.8 to 7.1 months at the 8.6 mg/kg and 10 mg/kg dose levels in March. The planned second-line combination study is expected to help the company gain experience with Varseta-M in irinotecan-naive patients over time. It plans to screen pancreatic and biliary tract cancer patients for EpCAM expression. McCarthy said EpCAM is expressed at some level in nearly all pancreatic and biliary tract cancer patients based on published literature and the company’s studies using its immunohistochemistry assay. About CytomX Therapeutics (NASDAQ:CTMX)CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform.